Evidence

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

April 26, 2017

PUBLICATION: Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. AUTHORS: Peter Beitsch, MD; Pat Whitworth, MD; Paul Baron, MD; Michael C. Rotkis, MD; Angela M. Mislowsky, MD; Paul D. Richards, MD; Mary K. Murray, MD; James V. Pellicane, MD; Carrie L. Dul, MD; Charles H. Nash, MD; Lisette Stork-Sloots, MSc; Femke de Snoo, MD, PhD; Sarah Untch, BS;…

Read more

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

July 6, 2016

PUBLICATION: Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6. AUTHORS: Peter Beitsch, Pat Whitworth, Paul Baron, James Pellicane, Tina Treece, Erin Yoder, Mark Gittleman, NBRST Investigators Group SUMMARY: This substudy showed that NAT significantly altered the genomic signature of the patient’s breast cancer compared with the patient’s pre-treatment genomic profile. These alterations occurred in a subtype-dependent manner, suggesting that…

Read more

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

August 15, 2012

PUBLICATION: Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Aug 15. AUTHORS: Nguyen B., Cusumano P.G., Deck K., Kerlin D., Garcia A.A., Barone J..L, Rivera E., Yao K., de Snoo F.A., van den Akker J., Stork-Sloots L., Generali D. SUMMARY: The concordance between BluePrint and IHC/FISH subtyping was 94% for the Luminal-type, 95% for the HER2-type, and…

Read more